PD168393 - EGFR 抑制劑 - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPD168393Cat. No.: HY-13896CAS No.: 194423-15-9分式: CHBrNO分量: 369.22作靶點: EGFR; Autophagy作通路: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Autophagy儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗

2、 DMSO : 30 mg/mL (81.25 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.7084 mL 13.5421 mL 27.0841 mL5 mM 0.5417 mL 2.7084 mL 5.4168 mL10 mM 0.2708 mL 1.3542 mL 2.7084 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 PD168393個強的，不可逆

3、轉(zhuǎn)的EGFR抑制劑，IC50是0.7 nM。IC50 & Target EGFR0.7 nM (IC50)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE戶使本產(chǎn)品發(fā)表的科研獻 J Cell Biochem. 2018 Mar;119(3):2911-2922.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Fry DW et al. Specific, irreversible inactivation of the epidermal growth

4、factor receptor and erbB2, by a new class of tyrosine kinaseinhibitor. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12022-7.2. Sun X et al. The activation of EGFR promotes myocardial tumor necrosis factor- production and cardiac failure in endotoxemia.Oncotarget. 2015 Nov 3;6(34):35478-95.3. Li G et

5、 al. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1. PLoS One. 2014 Sep19;9(9):e106349.4. White KJ et al. Irritant activation of epithelial cells is mediated via protease-dependent EGFR activation. J Invest Dermatol. 2011Feb;131(2):435-42.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-